Clinical Trials

29 enrolled

Stomach Neoplasms

NCT05638451 2024-06-05

Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients

CNS

Glioblastoma

NCT06227325 2024-01-26

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

27 enrolled

Stomach Neoplasms

NCT05164458 2023-12-28

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

Phase 1 Unknown

320 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06161909 2023-12-08

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

400 enrolled

Esophageal Neoplasms

NCT06120127 2023-11-07

IMPROVE

80 enrolled

Colorectal Neoplasms

NCT05250843 2023-10-13

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Phase 2/3 Unknown

90 enrolled

Carcinoma, Hepatocellular

NCT05307198 2023-10-10

RAIC

38 enrolled

Rectal Neoplasms

NCT05010434 2023-09-21

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

46 enrolled

Carcinoma, Hepatocellular

NCT06046963 2023-09-21

Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

35 enrolled

Ascites, Stomach Neoplasms

NCT06029829 2023-09-08

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

Carcinoma, Hepatocellular

NCT05795296 2023-08-30

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

NCT05971199 2023-08-02

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

27 enrolled

Carcinoma, Hepatocellular

NCT04724239 2023-08-01

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

48 enrolled

Colorectal Neoplasms

NCT04267549 2023-07-06

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

47 enrolled

Stomach Neoplasms

NCT05928897 2023-07-05

Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab

Stomach Neoplasms

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT04072107 2023-06-18

EP-STAR

110 enrolled

Nasopharyngeal Carcinoma

NCT05653180 2023-04-03

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

20 enrolled

Advanced Biliary Tract Cancer

NCT05781074 2023-03-24

CASTLE-08

25 enrolled

Advanced Biliary Tract Cancer

NCT05616390 2023-03-21

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT04194359 2023-03-17

Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

25 enrolled

Colorectal Neoplasms

NCT05749042 2023-03-01

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

70 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04872582 2023-02-23

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

33 enrolled

Nasopharyngeal Carcinoma

NCT05386524 2023-02-16

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

41 enrolled

Breast

Breast Neoplasms

NCT05720533 2023-02-09

Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT05029973 2023-02-08

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Carcinoma, Hepatocellular

NCT05225116 2023-02-08

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Phase 1 Unknown

20 enrolled

Carcinoma, Hepatocellular

NCT04984980 2023-01-26

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

37 enrolled

Biliary Tract Carcinoma

NCT05648071 2022-12-13

SPBPDC

Thoracic

Advanced Non-squamous Non-Small-Cell Lung Cancer

NCT03574402 2022-12-06

TRUMP

400 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05627414 2022-11-25

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Stomach Neoplasms

NCT05627427 2022-11-25

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

EndocrineGastrointestinal

Pancreatic Neoplasms, Carcinoma, Neuroendocrine

NCT05617430 2022-11-15

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

43 enrolled

Carcinoma, Hepatocellular

NCT04718909 2022-11-10

REGSIN

166 enrolled

Carcinoma, Hepatocellular

NCT05594381 2022-10-26

A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.

90 enrolled

Stomach Neoplasms

NCT04720716 2022-09-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

490 enrolled

Carcinoma, Hepatocellular

NCT05530785 2022-09-07

Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Phase NA Unknown

35 enrolled

Hepatocellular Carcinoma Non-resectable

NCT05524155 2022-09-01

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Colorectal Neoplasms

NCT05279677 2022-08-23

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colonic Neoplasms

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

1 enrolled

PD-1 Antibody

NCT04459611 2022-07-12

neoSCORE

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05438108 2022-06-29

SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Colorectal Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

120 enrolled

Breast

HER2+ Breast Cancer

NCT04174781 2022-06-09

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

61 enrolled

Carcinoma, Hepatocellular

NCT05201859 2022-05-06

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

150 enrolled

Nasopharyngeal Carcinoma

NCT05363722 2022-05-06

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Phase 1 Unknown

80 enrolled

Carcinoma, Hepatocellular

NCT05339581 2022-04-27

iPLENTY-pvtt

Phase NA Unknown

78 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05216237 2022-04-11

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

31 enrolled

Stomach Neoplasms

NCT05322187 2022-04-11

sPLENTY-pc

Phase 2/3 Unknown

15 enrolled